ANI Pharmaceuticals launched duloxetine delayed-release capsules, a generic version of Cymbalta®. The product will be available in 20 mg, 30 mg, and 60 mg strengths. U.S. annual sales for the market are approximately $247 million, according to IQVIA data.
President and CEO Nikhil Lalwani said the launch adds an alternative in a market with a limited number of suppliers. He said it could help support a stable supply for patients and providers.
The launch expands ANI’s generic pharmaceuticals portfolio and creates a potential new revenue stream.